Merck celebrates another win in Januvia patent battle against Viatris
Viatris has suffered its second stinging loss in as many weeks in its attempt to challenge Merck’s Januvia and Janumet patents.
A federal appeals court …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
